U.K. drug maker Shire PLC (SHP.LN) Friday said it intends to advance talks with regulators about developing its hyperactivity drug Vyvanse as a treatment for depression following the results of a clinical trial.

A mid-stage trial of Vyvanse in patients with residual depression following treatment with Lexapro, an antidepressant sold by Forest Laboratories Inc. (FRX), found patients receiving Vyvanse experienced an improvement in their symptoms compared to a dummy version.

Shire said it intends to ask regulators about developing Vyvanse as an add-on treatment for major depressive disorder and expects to start Phase III trials in patients with major depressive disorder in mid-2011.

-By Jason Douglas, Dow Jones Newswires; 44-20-7842-9272; jason.douglas@dowjones.com
Forest Road Acquisition (NYSE:FRX)
Historical Stock Chart
From Sep 2024 to Oct 2024 Click Here for more Forest Road Acquisition Charts.
Forest Road Acquisition (NYSE:FRX)
Historical Stock Chart
From Oct 2023 to Oct 2024 Click Here for more Forest Road Acquisition Charts.